Chapter 1. "Introduction: Motivations for Next-Generation ADCs" -Marc Damelin
Chapter 2. "Combining ADCs with Immuno-oncology Agents" -- Philipp Müller, Jonathan Rios-Doria, Jay Harper and Anthony Cao
Chapter 3. "Improving the Safety Profile of ADCs" -- MagaliGuffroy, HadiFalahatpisheh and Martin Finkelstein
Chapter 4. "Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development" -- Aman P. Singh and Dhaval K. Shah Chapter 5."Regulatory Considerations and Companion Diagnostics" - Elizabeth VanAlphen and Omar Perez
Chapter 6. "ADC Process Development and Manufacturing" - Olivier Marcq
Chapter 7. "HER2-Targeted ADCs: At the forefront of ADC technology development" - Kevin J. Hamblett
Chapter 8. "Next generation payloads for ADCs" - L. Nathan Tumey Chapter 9."Delivering more payload: High DAR ADCs" - Natalya Bodyak and Alexander V.Yurkovetskiy
Chapter 10."Site-Specific Antibody Drug Conjugates" - Feng Tian, Dowdy Jackson and Yun Bai
Chapter 11. "Bispecific and Biparatopic Antibody-Drug Conjugates" -- Frank Comer, Changshou Gao and Steve Coats
Chapter 12. "Targeting drug conjugates to the tumor microenvironment: Probody Drug Conjugates" -- Jack Lin and Jason Sagert
Chapter 13."Antibody-Drug Conjugates: Targeting the Tumor Microenvironment" - Alberto Dal Corso, SamueleCazzamalli and Dario Neri
Chapter 14. "Next Horizons: ADCs Beyond Oncology" -- Shan Yu, Andrew Lim and Matthew S. Tremblay
About the Author:
Marc Damelin is Senior Director, Biology at Mersana Therapeutics in Cambridge, Massachusetts. His group is responsible for the discovery of therapeutic ADCs enabled by Mersana's proprietary linker-payload-scaffold technologies. Prior, Marc spent 10 years at Pfizer Inc. in the Oncology Research Unit, where he led ADC discovery teams and ultimately oversaw the ADC portfolio. He received his Ph.D. in Biophysics from Harvard University and conducted postdoctoral research at Columbia University Medical School as a Fellow of the Damon Runyon Cancer Research Foundation.
